RDIF and rostec to establish production of the drug in blood plasma for treatment COVID-19
Holding “Nazimiye” rostec Corporation and the Russian direct investment Fund have agreed to launch a joint project for the production of the drug in blood plasma for treatment COVID-19. According to the press service of Rostec, the company has its own technology for production of human immunoglobulin, is able to counteract the virus.
Made on the basis of blood plasma of patients recover from a drug containing antibodies to the SARS coronavirus CoV-2, will be called “Biogas”, at the moment he has successfully passed the first phase of clinical trials.
According to the Director of Rostec Sergey Chemezov, after the registration of drug manufacturing can be deployed in four sites in Perm, Nizhny Novgorod, Tomsk and Ufa.
Investments obtained in the framework of cooperation with the FUND, will be used to purchase equipment, clinical trials, preparation of documents for registration of the drug.
